Filter documents Clear search

pdf icon

FSRH CEU Statement on Nexplanon® Insertion Site 15 January 2020

File size: 327kb | Date: 15 January 2020 | Clinical Statements - PDF

This CEU Statement provides guidance to healthcare professionals in response to a letter circulated by MSD (manufacturer of Nexplanon®) to healthcare professionals in the UK about updated guidance regarding the recommended Nexplanon® insertion site.

pdf icon

Telemedical abortion care: Safeguarding Young People

File size: 545kb | Date: 9 July 2021 | Clinical Statements - PDF

Statement from the Royal College of Obstetricians & Gynaecologists (RCOG), the Faculty of Sexual and Reproductive Healthcare and the British Society of Abortion Care Providers (BSACP) regarding the advent of telemedical abortion care and the safeguarding of young people.

pdf icon

FSRH CEU Statement: Contraception for Women with Eating Disorders (May 2021)

File size: 566kb | Date: 10 May 2021 | Clinical Statements - PDF

Sexually active women of reproductive age with eating disorders require effective contraception despite the fact that amenorrhoea and anovulation are common in this population. This statement provides clinicians with a resource for best helping women with eating disorders choose the most appropriate and acceptable contraception for them. Download and save the document here.

pdf icon

FSRH CEU statement Levosert 6 year license for contraception - Feb 2021

File size: 378kb | Date: 8 February 2021 | Clinical Statements - PDF

This statement notes that the Levosert® 52mg LNG-IUS has been licensed for contraceptive use for 6 years. Levosert remains licensed for 5 years for management of heavy menstrual bleeding and is not licensed for endometrial protection as part of HRT.

pdf icon

FSRH CEU Statement: Response to recently published “Bridge-It” study by Cameron, et al - November 2020

File size: 209kb | Date: 23 November 2020 | Clinical Statements - PDF

The FSRH CEU summarizes and comments on the Cameron, et al “Bridge-It” study, which found that women receiving levonorgestrel emergency contraception from a pharmacy are more likely to be using effective ongoing contraception if they are given a three-month supply of progestogen-only pill and facilitated access to local SRH services.